Rush University Medical Center has received a $5 million donation from Chicago philanthropists Robert and Emily King that will accelerate blood cancer immunotherapy research and the development of new treatment options.
The Commission on Cancer has granted the Rush University Cancer Center accreditation through 2020 following an extensive onsite survey that demonstrated how Rush has exceeded 34 quality of care standards and sustained excellence across four domains of care: access and service, satisfaction and well-being, quality of care and cancer outcomes.
Tempus, a technology company focused on helping doctors personalize cancer care, and Rush University Medical Center announced today a partnership to pursue their shared goal of providing customized treatment to cancer patients.
A leading authority on developing innovative immunotherapy treatments is Rush' new division chief of the Hematology, Oncology and Cell Therapy. Dr. Timothy Kuzel will focus on continuing to assemble multidisciplinary teams to craft individualized treatments for each patient.